Recent Updates
Recently added Catalysts

Opioid in low dose

Phase 2

Chronic Obstructive Pulmonary Disease (COPD) | Small molecule | Respiratory |Atlantic International Corp.|Last Updated: Jan 23, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment45

FDA Designations

No designations recorded

Clinical trial landscape

Opioid in low dose · 1 trial · 1 indication

Phase 2 1
NCT00982891Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED45 Analytics
PHASE2COMPLETED
Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
NCT0098289145
Unlock trial analytics

Study Endpoints

Primary Endpoints

To understand the experiences of patients and informal caregivers living with severe COPD, following the addition of opioid therapy to conventional treatment.
6 months

Secondary Endpoints

To explore the effect of opioid therapy on dyspnea and on quality of life, anxiety, depression, caregiver experiences and to determine proportion of patients finding opioids helpful at 4-6 months
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeSUPPORTIVE_CARE

Treatment Arms

ArmTypeDescription
Morphine, low dose, in addition to conventional treatmentEXPERIMENTALMorphine dose titration

Interventions

NameTypeDescription
Opioid (morphine sulphate) in low doseDRUGindividualized titration
Unlock Study Design Details

Eligibility Criteria

SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * We define advanced COPD as including those with severe COPD by CTS criteria (i.e., severe shortness of breath resulting in the patient being too breathless to leave the house, or breathlessness after dressing/undressing (i.e., Medical Research Council (MRC) score of 5), or the...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about Opioid in low dose

What is Opioid in low dose used for in COPD?

Opioid in low dose is an investigational small molecule being studied for the palliation of dyspnea, or shortness of breath, in patients with advanced Chronic Obstructive Pulmonary Disease (COPD). It is intended to address respiratory symptoms in this patient population.

Who makes Opioid in low dose?

Opioid in low dose is being developed by Atlantic International Corp., a company listed on the stock exchange under the ticker symbol ATLN. The company is conducting clinical research on this drug candidate for the treatment of dyspnea in advanced COPD.

What phase is Opioid in low dose in?

Opioid in low dose is currently in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that has not yet been approved by regulatory authorities. Further clinical studies would be needed to establish its safety and efficacy.

What clinical trials is Opioid in low dose in?

Opioid in low dose has been studied in one completed clinical trial with the identifier NCT00982891. This Phase 2 trial, titled 'Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD),' enrolled 45 participants in Canada and evaluated the drug for the relief of dyspnea in advanced COPD.

Is Opioid in low dose FDA approved?

Opioid in low dose is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the palliation of dyspnea in advanced COPD. The drug has completed one clinical trial, but it has not yet received regulatory approval for any use.